Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
| fusion
|  
|  
|  
|
t(6;11)(q24.1;p15.5) resulting in a NUP98-CCDC28A fusion in acute megakaryoblastic leukemia |
tumoral
| fusion
|  
|  
|  
|
fused with HOXD11 in t(5;11)(q35;p15.5) in acute myeloid leukemia |
tumoral
| fusion
|  
|  
|  
|
fused with TOP1 in t(11;20)(p15;q11) in therapy related myelodysplastic syndrome, and with HOXA13 int (7;11) (p15;p15) |
tumoral
| fusion
|  
|  
|  
|
fused with WHSC1L1 in t(8;11) (p11.2-p15) in acute myeloid leukemia, with ADD3 in t(10;11)(q25;p15) in T-cell acute lymphoblastic leukemia |
tumoral
| fusion
|  
|  
|  
|
with DDX10 in de novo or therapy related myeloid malignancies,with HOXD13 or FN1 in translocation t(2;11) (q35;p15) or t(2;11) (q31;p15) in acute myelomonocytic leukemia with inv11(p15-q22) |
tumoral
| fusion
|  
|  
|  
|
with PMX1 in translocation t(1;11) (q23;p15),with RAP1GDS1 in t(4;11)(q21;p15) in T cell acute lymphocitic leukemia,with PSIP1 in t (9;11) (p22;p15) in acute myeloid leukemia |
tumoral
| fusion
|  
|  
|  
|
to KDM5A in acute lymphoblastic leukemia |
tumoral
|  
|  
| --over
|  
|
of NUP98-HOXA9 represses myeloid-specific gene transcription, thereby contributing to differentiation block in leukemogenesis |
tumoral
| fusion
|  
|  
|  
|
NUP98-HOXD13 (NHD13) fusion in patients with myelodysplastic syndrome (MDS) and acute nonlymphocytic leukemia (ANLL) |
tumoral
|  
| translocation
|  
|  
|
t(3;11)(q12;p15)/NUP98-LNP1 fusion transcript in acute myeloid leukemia |
tumoral
| fusion
|  
|  
|  
|
NUP98/NSD1 identifies a previously unrecognized group of young acute myeloid leukemia with a distinct HOX gene expression pattern |
tumoral
| fusion
|  
|  
|  
|
POU1F1 is a fusion partner of NUP98 in acute myeloid leukemia with t(3;11)(p11;p15) ( |
tumoral
| fusion
|  
|  
|  
|
of NUP98 to KDM5A (t(11;15)(p15;q35)in acute megakaryoblastic leukemia (AMKL) |